171 related articles for article (PubMed ID: 34222029)
1. Lurbinectedin in Refractory Diffuse Malignant Peritoneal Mesothelioma: Report of Two Cases.
Gros L; Szturz P; Diciolla A; Kirchner V; Peters S; Schaefer N; Hubner M; Digklia A
Front Oncol; 2021; 11():704295. PubMed ID: 34222029
[TBL] [Abstract][Full Text] [Related]
2. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: patient selection and special considerations.
Enomoto LM; Shen P; Levine EA; Votanopoulos KI
Cancer Manag Res; 2019; 11():4231-4241. PubMed ID: 31190990
[TBL] [Abstract][Full Text] [Related]
3. Malignant peritoneal mesothelioma: a review.
Kim J; Bhagwandin S; Labow DM
Ann Transl Med; 2017 Jun; 5(11):236. PubMed ID: 28706904
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial.
de Boer NL; van Kooten JP; Burger JWA; Verhoef C; Aerts JGJV; Madsen EVE
BMJ Open; 2019 May; 9(5):e026779. PubMed ID: 31092657
[TBL] [Abstract][Full Text] [Related]
5. Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16).
Metaxas Y; Früh M; Eboulet EI; Grosso F; Pless M; Zucali PA; Ceresoli GL; Mark M; Schneider M; Maconi A; Perrino M; Biaggi-Rudolf C; Froesch P; Schmid S; Waibel C; Appenzeller C; Rauch D; von Moos R;
Ann Oncol; 2020 Apr; 31(4):495-500. PubMed ID: 32085891
[TBL] [Abstract][Full Text] [Related]
6. Malignant peritoneal mesothelioma literature review: past, present, and future.
Gregory SN; Sarvestani AL; Blakely AM
Dig Med Res; 2022 Jun; 5():. PubMed ID: 36061260
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial of intravenous versus bidirectional chemotherapy after cytoreductive surgery for malignant peritoneal mesothelioma.
Sugarbaker PH
Int J Surg Protoc; 2023 Dec; 27(3):108-117. PubMed ID: 38046900
[TBL] [Abstract][Full Text] [Related]
8. Conversion to Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma After Bidirectional Chemotherapy.
Le Roy F; Gelli M; Hollebecque A; Honoré C; Boige V; Dartigues P; Benhaim L; Malka D; Ducreux M; Elias D; Goéré D
Ann Surg Oncol; 2017 Nov; 24(12):3640-3646. PubMed ID: 28849389
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Malignant Peritoneal Mesothelioma.
Levý M; Boublíková L; Büchler T; Šimša J
Klin Onkol; 2019; 32(5):333-337. PubMed ID: 31610664
[TBL] [Abstract][Full Text] [Related]
10. Intraperitoneal paclitaxel for patients with primary malignant peritoneal mesothelioma: a phase I/II dose escalation and safety study-INTERACT MESO.
van Kooten JP; Dietz MV; Guchelaar NAD; Brandt-Kerkhof ARM; Koolen SLW; Burger JWA; Mathijssen RHJ; Verhoef C; Aerts JGJV; Madsen EVE
BMJ Open; 2022 Jun; 12(6):e062907. PubMed ID: 35732399
[TBL] [Abstract][Full Text] [Related]
11. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin in pediatric patients with peritoneal mesothelioma: a single institution experience and long term follow up.
Malekzadeh P; Good M; Hughes MS
Int J Hyperthermia; 2021; 38(1):326-331. PubMed ID: 34139940
[TBL] [Abstract][Full Text] [Related]
12. Update on the management of malignant peritoneal mesothelioma.
Sugarbaker PH
Transl Lung Cancer Res; 2018 Oct; 7(5):599-608. PubMed ID: 30450299
[TBL] [Abstract][Full Text] [Related]
13. Repeat cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent diffuse malignant peritoneal mesothelioma.
Huang Y; Alzahrani NA; Liauw W; Morris DL
Eur J Surg Oncol; 2015 Oct; 41(10):1373-8. PubMed ID: 26227745
[TBL] [Abstract][Full Text] [Related]
14. Advances in malignant peritoneal mesothelioma.
Cao S; Jin S; Cao J; Shen J; Hu J; Che D; Pan B; Zhang J; He X; Ding D; Gu F; Yu Y
Int J Colorectal Dis; 2015 Jan; 30(1):1-10. PubMed ID: 25331029
[TBL] [Abstract][Full Text] [Related]
15. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome.
Ihemelandu C; Bijelic L; Sugarbaker PH
Ann Surg Oncol; 2015 May; 22(5):1680-5. PubMed ID: 25120250
[TBL] [Abstract][Full Text] [Related]
16. Peritoneal mesothelioma.
Greenbaum A; Alexander HR
Transl Lung Cancer Res; 2020 Feb; 9(Suppl 1):S120-S132. PubMed ID: 32206577
[TBL] [Abstract][Full Text] [Related]
17. Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study.
Mark M; Rusakiewicz S; Früh M; Hayoz S; Grosso F; Pless M; Zucali P; Ceresoli GL; Maconi A; Schneider M; Froesch P; Tarussio D; Benedetti F; Dagher J; Kandalaft L; von Moos R; Tissot-Renaud S; Schmid S; Metaxas Y
ESMO Open; 2022 Jun; 7(3):100446. PubMed ID: 35427834
[TBL] [Abstract][Full Text] [Related]
18. Peritoneal mesothelioma in Sweden: A population-based study.
Cashin PH; Jansson Palmer G; Asplund D; Graf W; Syk I
Cancer Med; 2019 Oct; 8(14):6468-6475. PubMed ID: 31483564
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Mesothelioma: Experience of a Peritoneal Surface Malignancy Center.
Aydin N; Sardi A; Milovanov V; Nieroda C; Sittig M; Nunez MF; Jimenez W; Gushchin V
Am Surg; 2015 Dec; 81(12):1253-9. PubMed ID: 26736164
[TBL] [Abstract][Full Text] [Related]
20. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma.
Tan GH; Cheung M; Chanyaputhipong J; Soo KC; Teo MC
Ann Acad Med Singap; 2013 Jun; 42(6):291-6. PubMed ID: 23842770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
